Investor service announcement no. 6/2014
To: NASDAQ OMX Copenhagen Hørsholm, Denmark, 31 October, 2014
Veloxis Pharmaceuticals A/S to Host Conference Call discussing the FDA tentative approval of Envarsus® XR
Veloxis Pharmaceuticals A/S (OMX: VELO) Veloxis’ Management will host a conference call to discuss the FDA tentative approval of Envarsus® XR on Tuesday 4 November, 2014 at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM EST (New York),
To access the live conference call, please dial one of the following numbers:
+45 32 72 80 18 (Denmark)
+44 (0) 1452 555 131 (UK)
+1 866 682 8490 (USA)
For more information, please contact:
Veloxis Pharmaceuticals A/S
William J. Polvino
President & CEO
Tel: +1 732 321 3202
Email: wjp@veloxis.com
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis’ unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
